PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis

Lee, J.; Chaft, Jamie E.; Nicholas, Alan; Patterson, Alexander; Waqar, Saiama N.; Toloza, Eric M.; Haura, Eric B.; Raz, Dan J.; Reckamp, Karen L.; Merritt, Robert E.; Owen, Dwight H.; Finley, David J.; McNamee, Ciaran; Blasberg, Justin D.; Garon, Edward B.; Mitchell, Jason W.; Doebele, Robert C.; Baciewicz, Frank A.; Nagasaka, Misako; Pass, Harvey I.; Schulze, Katja; Phan, See‐Chun; Johnson, Ann; Bunn, Paul A.; Johnson, Bruce E.; Kris, Mark G.; Kwiatkowski, David J.; Wistuba, Ignacio I.; Carbone, David P.; Rusch, Valerie W.

doi:10.1016/j.jtho.2021.01.320

Cited by 67 publications

(73 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 14 II Single-arm cohort study 15 0/40/60 Pembrolizumab Two cycles 200 mg IV Q3W Safety, feasibility Lee et al. 18 II Single-arm cohort study 181 9/41/49 Atezolizumab Two cycles 1200 mg IV Q3W MPR Gao et al. 16 Ib Single-arm cohort study 40 20/35/45 Sintilimab Two cycles 200 mg IV Q3W Safety Besse et al.…”

Section: Resultsmentioning

confidence: 99%

“… 14 , n (%) 4/15 (27) 2/15 (13) Lee et al. 18 , n (%) 30/147 (20) a 10/147 (7) a Gao et al. 16 , n (%) 15/37 (40.5) 6/37 (16) Besse et al.…”

Section: Resultsmentioning

confidence: 99%

“… 14 , n (%) 0/15 (0) 1/15 (7) a 3/15 (20) Lee et al. 18 , n (%) 29/181 (16) 19/159 (12) b 9/181 (5) f Gao et al. 16 , n (%) 3/40 (7.5) 2/37 (5) 4/40 (10) Besse et al.…”

Section: Resultsmentioning

confidence: 99%

“… 26 There was no difference in these rates when considering the different groups (monotherapy–ICI, dual–ICI, chemoradiotherapy–ICI, radiotherapy–ICI, chemotherapy–ICI). There were various reasons reported for not proceeding to a resection: disease progression, 10 , 11 , 18 , 19 , 20 , 21 , 23 , 24 , 25 , 26 , 27 , 28 inadequate lung function, 24 , 27 persistent N2 disease, 26 unresectable disease, 21 , 23 , 25 trAEs, 10 , 27 location of tumor, 15 , 26 or patient refusal. 11 One study did not report on the specific reason for a patient not to proceed to the planned surgery.…”

Section: Resultsmentioning

confidence: 99%

“…pneumonitis or pneumonia). 15 , 16 , 18 , 27 In the chemotherapy–ICI group, reported rates ranged from 0% 29 to 67%. 21 Here, the reported trAEs were attributed to hematological disorders, 19 , 22 , 23 , 24 ipilimumab-related diarrhea, 26 and chemotherapy-related toxicities.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review

Ulas

Dickhoff²,

Schneiders

et al. 2021

ESMO Open

View full text Add to dashboard Cite

Background The neoadjuvant use of immune checkpoint inhibitors (ICIs) in resectable non-small-cell lung cancer (NSCLC) is currently an area of active ongoing research. The place of neoadjuvant ICIs in the treatment guidelines needs to be determined. We carried out a systematic review of published data on neoadjuvant ICIs in resectable NSCLC to study its efficacy and safety. Patients and methods A literature search was carried out using the MEDLINE (PubMed) and Embase databases to retrieve articles and conference abstracts of clinical trials measuring the efficacy [major pathological response (MPR) and pathological complete response (pCR)] and safety (failure to undergo resection, surgical delay, treatment-related adverse events (trAEs) grade ≥3) of neoadjuvant immunotherapy in resectable NSCLC until July 2021. Results Nineteen studies with a total of 1066 patients were included in this systematic review. Neoadjuvant immunotherapy was associated with improved pathological response rates, especially in combination with chemotherapy. Using mono ICI, dual therapy–ICI, chemoradiation–ICI, radiotherapy–ICI, and chemo–ICI, the MPR rates were 0%-45%, 50%, 73%, 53%, and 27%-86%, respectively. Regarding pCR, the rates were 7%-16%, 33%-38%, 27%, 27%, and 9%-63%, respectively. Safety endpoints using monotherapy–ICI, dual therapy–ICI, chemoradiation–ICI, radiotherapy–ICI, and chemo–ICI showed a failure to undergo resection in 0%-17%, 19%-33%, 8%, 13%, and 0%-46%, respectively. The trAEs grade ≥3 rates were 0%-20%, 10%-33%, 7%, 23%, and 0%-67%, respectively. Conclusion In patients with resectable NSCLC stage, neoadjuvant immunotherapy can improve pathological response rates with acceptable toxicity. Further research is needed to identify patients who may benefit most from this approach, and adequately powered trials to establish clinically meaningful benefits are awaited.

show abstract

Section: Resultsmentioning

confidence: 99%

“… 14 , n (%) 4/15 (27) 2/15 (13) Lee et al. 18 , n (%) 30/147 (20) a 10/147 (7) a Gao et al. 16 , n (%) 15/37 (40.5) 6/37 (16) Besse et al.…”

Section: Resultsmentioning

confidence: 99%

“… 14 , n (%) 0/15 (0) 1/15 (7) a 3/15 (20) Lee et al. 18 , n (%) 29/181 (16) 19/159 (12) b 9/181 (5) f Gao et al. 16 , n (%) 3/40 (7.5) 2/37 (5) 4/40 (10) Besse et al.…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review

Ulas

Dickhoff²,

Schneiders

et al. 2021

ESMO Open

View full text Add to dashboard Cite

show abstract

Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art

Kang

Zhang

Zhong

2021

Cancer Communications

101

View full text Add to dashboard Cite

Lung cancer mortality has decreased over the past decade and can be partly attributed to advances in targeted therapy and immunotherapy. Immune checkpoint inhibitors (ICIs) have rapidly evolved from investigational drugs to standard of care for the treatment of metastatic non‐small cell lung cancer (NSCLC). In particular, antibodies that block inhibitory immune checkpoints, such as programmed cell death protein 1 (PD‐1) and programmed cell death 1 ligand 1 (PD‐L1), have revolutionized the treatment of advanced NSCLC, when administered alone or in combination with chemotherapy. Immunotherapy is associated with higher response rates, improved overall survival (OS), and increased tolerability compared with conventional cytotoxic chemotherapy. These benefits may increase the utility of immunotherapy and its combinational use with chemotherapy in the neoadjuvant treatment of patients with NSCLC. Early findings from various ongoing clinical trials suggest that neoadjuvant ICIs alone or combined with chemotherapy may significantly reduce systemic recurrence and improve long‐term OS or cure rates in resectable NSCLC. Here we further summarize the safety and efficacy of various neoadjuvant treatment regimens including immunotherapy from ongoing clinical trials and elaborate the role of neoadjuvant immunotherapy in patients with resectable NSCLC. In addition, we discuss several unresolved challenges, including the evaluations to assess neoadjuvant immunotherapy response, the role of adjuvant treatment after neoadjuvant immunotherapy, the efficacy of treatment for oncogenic‐addicted tumors, and predictive biomarkers. We also provide our perspective on ways to overcome current obstacles and establish neoadjuvant immunotherapy as a standard of care.

show abstract

Non‐small cell lung cancer in China

Chen

Liu

Wen

et al. 2022

Cancer Communications

285

View full text Add to dashboard Cite

In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors for lung cancer include tobacco use, family history, radiation exposure, and the presence of chronic lung diseases. Most early‐stage non‐small cell lung cancer (NSCLC) patients miss the optimal timing for treatment due to the lack of clinical presentations. Population‐based nationwide screening programs are of significant help in increasing the early detection and survival rates of NSCLC in China. The understanding of molecular carcinogenesis and the identification of oncogenic drivers dramatically facilitate the development of targeted therapy for NSCLC, thus prolonging survival in patients with positive drivers. In the exploration of immune escape mechanisms, programmed cell death protein 1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitor monotherapy and PD‐1/PD‐L1 inhibitor plus chemotherapy have become a standard of care for advanced NSCLC in China. In the Chinese Society of Clinical Oncology's guidelines for NSCLC, maintenance immunotherapy is recommended for locally advanced NSCLC after chemoradiotherapy. Adjuvant immunotherapy and neoadjuvant chemoimmunotherapy will be approved for resectable NSCLC. In this review, we summarized recent advances in NSCLC in China in terms of epidemiology, biology, molecular pathology, pathogenesis, screening, diagnosis, targeted therapy, and immunotherapy.

show abstract

PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis

Cited by 67 publications

References 0 publications

Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review

Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review

Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art

Non‐small cell lung cancer in China

Contact Info

Product

Resources

About